Characteristics of the study sample
| . | All patients n = 358 . | AML n = 238 . | MDS n = 120 . |
|---|---|---|---|
| Age at diagnosis in years, median (IQR) | 70 (17) | 67 (17) | 75 (15) |
| Age at diagnosis in years, n (%) | |||
| ≥70 y | 187 (52.2) | 104 (43.7) | 83 (69.2) |
| <70 y | 171 (47.8) | 134 (56.3) | 37 (30.8) |
| Race, n (%) | |||
| White | 311 (86.9) | 199 (83.6) | 112 (93.3) |
| Black | 17 (4.7) | 16 (6.7) | 1 (0.8) |
| Other (Asian, Hispanic, not stated) | 30 (8.4) | 23 (9.7) | 7 (5.8) |
| ECOG-PS before death, n (%)* | |||
| 0 | 8 (4.2) | 7 (5.5) | 1 (1.6) |
| 1 | 28 (14.7) | 21(16.5) | 7 (11.1) |
| ≥2 | 154 (81.1) | 99 (78.0) | 55 (87.4) |
| ECOG-PS at diagnosis, n (%)† | |||
| 0 | 42 (20.5) | 29 (20.4) | 13 (20.6) |
| 1 | 83 (40.5) | 63 (44.4) | 20 (31.8) |
| ≥2 | 80 (39.0) | 50 (35.2) | 30 (47.6) |
| Number of comorbidities [median (IQR)] | 3 (3) | 3 (3) | 4 (3) |
| Comorbidities, n (%) | |||
| Hypertension | 192 (53.6) | 120 (50.4) | 72 (60.0) |
| Hyperlipidemia | 134 (37.4) | 83 (34.9) | 51 (42.5) |
| Diabetes | 77 (21.5) | 44 (18.5) | 33 (27.5) |
| Chronic obstructive pulmonary disease | 57 (15.9) | 32 (13.5) | 25 (20.8) |
| Coronary artery disease | 61 (17.0) | 30 (12.6) | 31 (25.8) |
| Disease status at first hematology visit, n (%) | |||
| New diagnosis | 226 (63.1) | 159 (66.8) | 67 (55.8) |
| Relapsed disease/disease progression | 31 (8.7) | 19 (8.0) | 12 (10.0) |
| Other‡ | 101 (28.2) | 60 (25.2) | 41 (34.2) |
| Intent of care at first visit, n (%) | |||
| Curative | 47 (13.1) | 37 (15.6) | 10 (8.3) |
| Palliative | 156 (43.6) | 92 (38.7) | 64 (53.3) |
| Not stated | 155 (43.3) | 109 (45.8) | 46 (38.3) |
| Geographical location | |||
| Urban | 268 (74.9) | 60 (25.2) | 30 (25.0) |
| Rural | 90 (25.1) | 178 (74.8) | 90 (75.0) |
| . | All patients n = 358 . | AML n = 238 . | MDS n = 120 . |
|---|---|---|---|
| Age at diagnosis in years, median (IQR) | 70 (17) | 67 (17) | 75 (15) |
| Age at diagnosis in years, n (%) | |||
| ≥70 y | 187 (52.2) | 104 (43.7) | 83 (69.2) |
| <70 y | 171 (47.8) | 134 (56.3) | 37 (30.8) |
| Race, n (%) | |||
| White | 311 (86.9) | 199 (83.6) | 112 (93.3) |
| Black | 17 (4.7) | 16 (6.7) | 1 (0.8) |
| Other (Asian, Hispanic, not stated) | 30 (8.4) | 23 (9.7) | 7 (5.8) |
| ECOG-PS before death, n (%)* | |||
| 0 | 8 (4.2) | 7 (5.5) | 1 (1.6) |
| 1 | 28 (14.7) | 21(16.5) | 7 (11.1) |
| ≥2 | 154 (81.1) | 99 (78.0) | 55 (87.4) |
| ECOG-PS at diagnosis, n (%)† | |||
| 0 | 42 (20.5) | 29 (20.4) | 13 (20.6) |
| 1 | 83 (40.5) | 63 (44.4) | 20 (31.8) |
| ≥2 | 80 (39.0) | 50 (35.2) | 30 (47.6) |
| Number of comorbidities [median (IQR)] | 3 (3) | 3 (3) | 4 (3) |
| Comorbidities, n (%) | |||
| Hypertension | 192 (53.6) | 120 (50.4) | 72 (60.0) |
| Hyperlipidemia | 134 (37.4) | 83 (34.9) | 51 (42.5) |
| Diabetes | 77 (21.5) | 44 (18.5) | 33 (27.5) |
| Chronic obstructive pulmonary disease | 57 (15.9) | 32 (13.5) | 25 (20.8) |
| Coronary artery disease | 61 (17.0) | 30 (12.6) | 31 (25.8) |
| Disease status at first hematology visit, n (%) | |||
| New diagnosis | 226 (63.1) | 159 (66.8) | 67 (55.8) |
| Relapsed disease/disease progression | 31 (8.7) | 19 (8.0) | 12 (10.0) |
| Other‡ | 101 (28.2) | 60 (25.2) | 41 (34.2) |
| Intent of care at first visit, n (%) | |||
| Curative | 47 (13.1) | 37 (15.6) | 10 (8.3) |
| Palliative | 156 (43.6) | 92 (38.7) | 64 (53.3) |
| Not stated | 155 (43.3) | 109 (45.8) | 46 (38.3) |
| Geographical location | |||
| Urban | 268 (74.9) | 60 (25.2) | 30 (25.0) |
| Rural | 90 (25.1) | 178 (74.8) | 90 (75.0) |
AML, Acute myeloid leukemia; ECOG, Eastern Cooperative Oncology Group performance status; IQR, Interquartile range; MDS, Myelodysplastic syndrome.
168 patients did not have data for this variable in their medical record.
153 patients did not have data for this variable in their medical record.
Included patients who were transferring care, being evaluated for a second opinion, or their diagnosis was greater than 4 weeks after their initial visit.